牛牛AI助理已提取核心訊息
Virpax Pharmaceuticals, Inc. (VRPX) has reported a transaction involving Chief Scientific Officer Sheila Mathias. The transaction took place on January 29, 2024. However, the announcement did not disclose the number of shares transacted, the nature of the shares, the transaction price, or the total value of the shares. Additionally, the number of shares held by Mathias after the transaction was not provided. This information is typically relevant for investors to assess the confidence of company insiders in the firm's prospects.
Virpax Pharmaceuticals, Inc. (VRPX) has reported a transaction involving Chief Scientific Officer Sheila Mathias. The transaction took place on January 29, 2024. However, the announcement did not disclose the number of shares transacted, the nature of the shares, the transaction price, or the total value of the shares. Additionally, the number of shares held by Mathias after the transaction was not provided. This information is typically relevant for investors to assess the confidence of company insiders in the firm's prospects.
Virpax Pharmicals, Inc.（VRPX）報告了一筆涉及首席科學官希拉·馬蒂亞斯的交易。該交易於 2024 年 1 月 29 日進行。但是，該公告沒有透露交易的股票數量、股票的性質、交易價格或股票的總價值。此外，沒有提供交易後馬蒂亞斯持有的股票數量。這些信息通常與投資者評估公司內部人士對公司前景的信心有關。
Virpax Pharmicals, Inc.（VRPX）報告了一筆涉及首席科學官希拉·馬蒂亞斯的交易。該交易於 2024 年 1 月 29 日進行。但是，該公告沒有透露交易的股票數量、股票的性質、交易價格或股票的總價值。此外，沒有提供交易後馬蒂亞斯持有的股票數量。這些信息通常與投資者評估公司內部人士對公司前景的信心有關。
有用
沒用
